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EssentialsGene therapy is a potential long‐term treatment for hemophilia A.Hemophilia A patients were recruited in the UK and tested for preexisting immunity to AAV5 and AAV8.21% of patients had antibodies against AAV5 and 23% had antibodies against AAV8.25% of patients had inhibitors to AAV5 and 38% of patients had inhibitors to AAV8.

1. INTRODUCTION {#rth212177-sec-0008}
===============

Current treatment for hemophilia A involves administration of factor concentrates to prevent or treat bleeds. Although replacement of FVIII has improved life expectancy and quality, limitations include frequent infusions at high costs and the risk of inhibitor formation.[1](#rth212177-bib-0001){ref-type="ref"}, [2](#rth212177-bib-0002){ref-type="ref"} Gene therapy is a potential alternative long‐term treatment option that works by producing endogenous FVIII following a single intravenous infusion of a vector containing the appropriate genetic code that has trophism for the liver.[3](#rth212177-bib-0003){ref-type="ref"} This enables the liver to produce relevant factor and even modest increases (plasma level of 2 ng/mL resulting in an increase in activity of 1%) can ameliorate severe forms of the disease.[4](#rth212177-bib-0004){ref-type="ref"} To date, gene therapy has been successfully used to treat hemophilia B[5](#rth212177-bib-0005){ref-type="ref"}, [6](#rth212177-bib-0006){ref-type="ref"}, [7](#rth212177-bib-0007){ref-type="ref"}, [8](#rth212177-bib-0008){ref-type="ref"}, [9](#rth212177-bib-0009){ref-type="ref"} and recently successful gene transfer has been reported in hemophilia A.[10](#rth212177-bib-0010){ref-type="ref"}

The adeno‐associated virus (AAV) serves as a promising gene delivery system as it can transduce dividing and non‐dividing cells and has not been associated with any disease.[11](#rth212177-bib-0011){ref-type="ref"}, [12](#rth212177-bib-0012){ref-type="ref"}, [13](#rth212177-bib-0013){ref-type="ref"} Adeno‐associated viruses are small, non‐enveloped single stranded, DNA viruses belonging to the *Parvoviridae* family and *Dependovirus* genus that cannot replicate autonomously and require a helper virus such as herpes simplex or adeno virus.[14](#rth212177-bib-0014){ref-type="ref"} Preexisting immunity against AAV vectors may represent a major barrier in gene transfer which could potentially result in clearance of the vector before it reaches the target cell.[9](#rth212177-bib-0009){ref-type="ref"}, [15](#rth212177-bib-0015){ref-type="ref"} The impact of preexisting immunity suggests that screening patients for seroprevalence may help identify those most likely to benefit from gene transfer.

Seroprevalence to different AAV serotypes is measured by either: (a) total antibody binding to the AAV capsid via immunoassay, or (b) detection of inhibitors that neutralize in vitro and in vivo the ability of AAV vectors to transduce.[16](#rth212177-bib-0016){ref-type="ref"} Immunoassay is a capture‐based method to detect antibodies capable of binding to the AAV capsid. The AAV capsid or peptide is coated on a plate, plasma or serum added, and antibodies detected with a secondary reagent.[17](#rth212177-bib-0017){ref-type="ref"} In vitro cell‐based assays use a reporter AAV vector that is incubated with the test sample before transduction of a cell line. These are amongst the most widely used methods of determining anti‐AAV neutralizing factors and the transduction inhibition assay is considered a standard.[18](#rth212177-bib-0018){ref-type="ref"}

With the clinical application of gene therapy using AAV5 and AAV8 in hemophilia,[7](#rth212177-bib-0007){ref-type="ref"}, [19](#rth212177-bib-0019){ref-type="ref"} this study aimed to measure the prevalence of these serotypes using assays that measure transduction inhibition and total antibody level in the UK hemophilia A population. Secondary aims included measuring differences in the prevalence of AAV5 and AAV8 in those who were exposed to plasma derived products and those who were not. Furthermore, differences in seroprevalence of AAV5 and AAV8 based on human immunodeficiency virus (HIV) and hepatitis C status as well as exposure were also assessed.

2. MATERIALS AND METHODS {#rth212177-sec-0009}
========================

Plasma samples from a total of 101 hemophilia A patients recruited from seven UK hemophilia centers were tested for preexisting neutralizing factors to AAV5 and AAV8 using transduction inhibition (TI) activity and total antibody assay (TAb). Favourable ethical opinion for this study was obtained from the National Research Ethics Committee North West--Liverpool Central, study number 15/NW/0469. The AAV5 assays were developed by the department of Bioanalytical Sciences at Biomarin Pharmaceutical Inc and the AAV 8 assays were developed by Genosafe. The information on HIV and hepatitis C was obtained from historical medical records.

2.1. AAV5 and AAV8 total antibodies assay for human plasma {#rth212177-sec-0010}
----------------------------------------------------------

Total antibodies against AAV5 were measured in human plasma using a validated sequential bridging electrochemiluminescence (ECL) assay on the MSD platform as described previously.[20](#rth212177-bib-0020){ref-type="ref"} Sample results were expressed as an signal of noise (S/N) value, calculated by dividing sample ECL units by negative control ECL units. Samples that had S/N values \>1.15 were considered positive. AAV5 TAb titers were determined as the reciprocal dilution of plasma samples at the titer cut point, S/N = 1.30. Average sensitivity for measuring antibodies to AAV5 was 4.5 ng/mL.

Total IgG antibodies to AAV8 were measured using a previously published ELISA technique.[18](#rth212177-bib-0018){ref-type="ref"} All samples with a mean optical density of \>0.506 were considered and results reported as the reciprocal titer at the cut point. As there are no human anti‐AAV8 monoclonal antibodies available, the AAV8 limit of detection was determined to be 18.8 μg/mL using human intravenous immunoglobulins (IVIg) solution.

2.2. Cell‐based AAV5 and AAV8 transduction inhibition titer assay for human plasma {#rth212177-sec-0011}
----------------------------------------------------------------------------------

A validated AAV5 TI assay for human plasma samples has been previously described.[20](#rth212177-bib-0020){ref-type="ref"} AAV5 TI titers were determined as the reciprocal dilution of plasma samples at the titer cut point, 44.9% transduction of the negative control. The method used to measure the neutralising effect of AAV8 has also been previously described.[18](#rth212177-bib-0018){ref-type="ref"} AAV8 TI titers were determined as the first reciprocal dilution at which \>38.4% inhibition of transduction by comparison with the negative control.

2.3. Statistical analysis {#rth212177-sec-0012}
-------------------------

Continuous variables are presented as median and interquartile range (IQR) and categorical data as frequency and percentages. To evaluate differences between groups, Pearsons\'s chi‐square test was used when the expected cell frequencies were equal to or greater than 5 and Fisher\'s exact test was used when the expected numbers were less than 5. Univariate analysis was performed to identify significant variables and those significant were used in the multivariate logistic regression analysis to identify the independent predictive variables. *P* values (two‐tailed) \<0.050 was considered statistically significant. Data were analyzed using SPSS version 23 (IBM, Armonk, New York).

3. RESULTS {#rth212177-sec-0013}
==========

Of the 101 patients recruited, one was excluded as the patient was not previously treated with FVIII. Results were analysed for 100 patients and descriptive characteristics of the population are presented in Table [1](#rth212177-tbl-0001){ref-type="table"}.

###### 

Demographics of the hemophilia A cohort

                                Median (IQR)
  ----------------------------- -----------------
  Age                           38 (27‐57)
  Weight (kg)                   78 (70‐88.8)
  Baseline FVIII level          No. of patients
   \<1 IU/dL                    60
   1‐5 IU/dL                    14
   \>5 IU/dL                    26
  Exposure to plasma products   86
  Treatment                     
   Prophylaxis                  45
   On‐demand                    55
   HIV positive                 6
   Hepatitis C exposed          42
   Hepatitis C positive         22

John Wiley & Sons, Ltd

The number of positive and negative patients for AAV5 and AAV8 based on the TI and TAb assays are presented in Table [2](#rth212177-tbl-0002){ref-type="table"}. In this study, positivity in either or both assays were used as a measure of seroprevalence. Seropositivity using TI and TAb assays are presented in Table [3](#rth212177-tbl-0003){ref-type="table"}.

###### 

Seroprevalence of AAV5 and AAV8 in the United Kindgom based on transduction inhibition and total antibodies assays. Percentage of patients who were positive for both AAV5 and AAV8 as measured by transduction inhibition and total antibodies assays

  \% Positive patients                  
  ---------------------- ---- ---- ---- ----
  AAV 5                  21   25   30   16
  AAV 8                  23   38   40   21
  AAV 5 & AAV 8          15   23   24   15

John Wiley & Sons, Ltd

###### 

Comparison (%) between the transduction inhibition and total antibodies assays for AAV5 and AAV8

  Total antibody (TAb)/**t**ransduction Inhibition (TI) assay   AAV 5 (%)   AAV 8 (%)
  ------------------------------------------------------------- ----------- -----------
  TAb− TI−                                                      70          60
  TAb+ TI+                                                      16          21
  TAb+ TI−                                                      5           2
  TAb− TI+                                                      9           17

John Wiley & Sons, Ltd

In patients positive for AAV5 the TI assay titers ranged from \<2 to \>256 and for the TAb assay the range was 57 to 2246. In AAV8 positive patients TAb assay titers ranged from 125 to 11 949 and for the TI assay the ranges were 3.35 to \>256. No significant correlation was observed between TAb and TI titers for AAV5 (*r* = 0.68, *P *= 0.064), TAb and TI titers for AAV8 (*r* = 0.62, *P *= 0.070) and TI titers between AAV5 and AAV8 (*r* = 0.56, *P *= 0.087). A significant correlation (*r* = 0.77, *P *= 0.001) was observed in TAb titers between AAV5 and AAV8 (Figure [1](#rth212177-fig-0001){ref-type="fig"}). Relationships between exposure to plasma products, HIV and hepatitis C status, hepatitis C exposure and treatment were assessed, results were available for all 100 patients and are presented in Table [4](#rth212177-tbl-0004){ref-type="table"}. Mutlivariate analysis of increasing age and seroprevalence of both AAV5 and AAV8 are presented in Table [5](#rth212177-tbl-0005){ref-type="table"}.

![Correlation of total antibodies titers of AAV5 and AAV8 in the adult UK hemophilia A population (*r* = −0.77, *P* = 0.001)](RTH2-3-261-g001){#rth212177-fig-0001}

###### 

Relationships of AAV5 and AAV8 seroprevalence with plasma product use, human immunodeficiency virus status and hepatitis C (exposure and status) (% positive)

             Plasma (% positive)                           HIV (% positive)   Hepatitis C exposure (% positive)             Hepatitis C status (% positive)
  ---------- --------------------------------------------- ------------------ --------------------------------------------- ---------------------------------------------
  AAV5 TI    28                                            17                 40[\*](#rth212177-note-0001){ref-type="fn"}   36
  AAV5 TAb   22                                            17                 33[\*](#rth212177-note-0001){ref-type="fn"}   41[\*](#rth212177-note-0001){ref-type="fn"}
  AAV8 TI    41                                            17                 48                                            50
  AAV8 TAb   27[\*](#rth212177-note-0001){ref-type="fn"}   0                  33[\*](#rth212177-note-0001){ref-type="fn"}   36

\**P *\<* *0.05.

John Wiley & Sons, Ltd

###### 

Multivariate analysis of increasing age and seroprevalence of AAV5 and AAV8

              Age \<38 y   Age ≥38 y   Number of patients   OR (95% CI)
  ----------- ------------ ----------- -------------------- ------------------
  AAV5 TI                                                   
   Negative   47           32          79                   0.16 (0.04‐0.52)
   Positive   4            17          21                   
  AAV5 TA                                                   
   Negative   45           30          75                   0.21 (0.08‐0.56)
   Positive   6            19          25                   
  AAV8 TI                                                   
   Negative   46           31          77                   0.16 (0.05‐0.52)
   Positive   4            17          21                   
   Negative   38           21          59                   0.32 (0.13‐0.74)
   Positive   12           25          37                   

John Wiley & Sons, Ltd

4. DISCUSSION {#rth212177-sec-0014}
=============

In the present study, patient samples were tested for inhibitors of transduction and total antibodies for AAV5 and 8. We found that 21% of patients had antibodies to AAV5 and 23% of patients had antibodies to AAV8. Twenty‐five percent of patients exhibited inhibitors to AAV5 transduction and 38% of patients had inhibitors of AAV8 transduction. Thirty percent of patients were positive in either assay for AAV5 and 40% for AAV8. Fifteen percent had antibodies against both AAV5 and AAV8, 23% had inhibitors against both capsids, and 24% were positive in both assays for both AAV5 and AAV8.

Previous studies on AAV seroprevalence have indicated that following exposure there is production of antibodies against AAV from all four IgG subclasses which harbor neutralizing properties but other unidentified factors within individuals may also be present.[21](#rth212177-bib-0021){ref-type="ref"} Therefore, current estimates of seroprevalence encompass measures of antibodies against AAV or other neutralizing factors (Table [6](#rth212177-tbl-0006){ref-type="table"}).

###### 

Current estimates of the seroprevalence of AAV 5 and AAV 8

  Authors                                                                                        Region                            n     Population                    AAV 5 antibodies (%)   AAV 8 antibodies (%)   AAV 5 neutralizing factors (%)   AAV 8 neutralizing factors (%)
  ---------------------------------------------------------------------------------------------- --------------------------------- ----- ----------------------------- ---------------------- ---------------------- -------------------------------- --------------------------------
  Boutin et al[21](#rth212177-bib-0021){ref-type="ref"}                                          France                            226   Healthy adults                40                     38                     3.2                              19
  Calcedo et al[44](#rth212177-bib-0044){ref-type="ref"}                                         Australia, Europe, Africa, USA,   100   Healthy adults                ---                    5‐32                   ---                              ---
  Liu et al[45](#rth212177-bib-0045){ref-type="ref"}                                             China                             500   Healthy children and adults   40.2                   82                     ---                              ---
  Liu et al[45](#rth212177-bib-0045){ref-type="ref"}                                             China                             270   HIV‐1 infected                ---                    ---                    37                               ---
  Li et al[26](#rth212177-bib-0026){ref-type="ref"}, [43](#rth212177-bib-0043){ref-type="ref"}   Thailand, USA                     62    Paediatric hemophilia A       25.8                   22.6                   ---                              ---
  Mimuro et al[47](#rth212177-bib-0047){ref-type="ref"}                                          Japan                             85    Healthy adults                37.6                   32.9                   ---                              ---
  Mimuro et al[47](#rth212177-bib-0047){ref-type="ref"}                                          Japan                             59    Hemophilia                    35.6                   32.9                   ---                              ---
  Falese et al[20](#rth212177-bib-0020){ref-type="ref"}                                          USA                               100   Healthy adults                5                      ---                    24                               ---
  Falese et al[20](#rth212177-bib-0020){ref-type="ref"}                                          USA                               24    Hemophilia A                  8                      ---                    8                                ---

John Wiley & Sons, Ltd

Currently, inhibitors of transduction to different AAV serotypes are determined by either in vitro or in vivo methods.[16](#rth212177-bib-0016){ref-type="ref"} Previous studies have demonstrated that several factors impact results including: assay sensitivity based on starting dilution, cell lines used for in vitro transduction, quantity of input AAV vector per cell, temperature, incubation time, volume of human sample used for AAV interaction, reporter transgene, eg, luciferase, LacZ etc., culture duration after addition of AAV transduction and heat inactivation of complement proteins.[5](#rth212177-bib-0005){ref-type="ref"}, [15](#rth212177-bib-0015){ref-type="ref"}, [21](#rth212177-bib-0021){ref-type="ref"}, [22](#rth212177-bib-0022){ref-type="ref"}, [23](#rth212177-bib-0023){ref-type="ref"}, [24](#rth212177-bib-0024){ref-type="ref"}, [25](#rth212177-bib-0025){ref-type="ref"}, [26](#rth212177-bib-0026){ref-type="ref"}, [27](#rth212177-bib-0027){ref-type="ref"}, [28](#rth212177-bib-0028){ref-type="ref"}, [29](#rth212177-bib-0029){ref-type="ref"}, [30](#rth212177-bib-0030){ref-type="ref"}, [31](#rth212177-bib-0031){ref-type="ref"}, [32](#rth212177-bib-0032){ref-type="ref"}, [33](#rth212177-bib-0033){ref-type="ref"}, [34](#rth212177-bib-0034){ref-type="ref"}, [35](#rth212177-bib-0035){ref-type="ref"}, [36](#rth212177-bib-0036){ref-type="ref"}, [37](#rth212177-bib-0037){ref-type="ref"}, [38](#rth212177-bib-0038){ref-type="ref"}, [39](#rth212177-bib-0039){ref-type="ref"}, [40](#rth212177-bib-0040){ref-type="ref"}, [41](#rth212177-bib-0041){ref-type="ref"}, [42](#rth212177-bib-0042){ref-type="ref"}, [43](#rth212177-bib-0043){ref-type="ref"} In vitro assays were used in this study and the cut‐off titer values at which patients were considered positive for total antibodies was set at \>1.15 for AAV5 and \>0.506 for AAV8. Transduction inhibiton positive cut‐off titers were 44.9% for AAV5 and 38.4% for AAV8. These cut‐off values were determined by statistically analysing sufficient numbers of samples from healthy popluations, ensure distribution was normal by removing outliers and setting the desired rate of false positive results, generally 1%‐5%.[18](#rth212177-bib-0018){ref-type="ref"}, [20](#rth212177-bib-0020){ref-type="ref"} No significant correlations were observed between the TAb and TI titers against either capsid, specifically AAV5 (*r* = 0.68) or AAV8 (*r* = 0.62) nor when comparing the inhibitor titer values between AAV5 vs AAV8 (*r* = 0.56). It is noteworthy that in comparing antibody or TI titers between the two AAVs, differences in the quantity of virus employed in the cell‐based assays is likely to result in different sensitivities of the AAV5 vs AAV8 assays and hence should be taken into account. A significant correlation was observed between TAb titers of AAV5 and AAV8 confirming the existence of cross reactivity which has been observed in previous studies.[21](#rth212177-bib-0021){ref-type="ref"}, [44](#rth212177-bib-0044){ref-type="ref"}

A previous study in hemophilia B demonstrated that neutralizing antibodies at titers lower than 1:10 could completely neutralize large vector doses with undetectable transgene expression.[9](#rth212177-bib-0009){ref-type="ref"} Currently, there is a lack of standardization of assays that measure neutralizing activity and total antibodies, therefore there is a variation in cut‐off titer values where participants are considered positive. Previous studies set the cut‐off positive titer at ≥50%,[21](#rth212177-bib-0021){ref-type="ref"}, [26](#rth212177-bib-0026){ref-type="ref"}, [45](#rth212177-bib-0045){ref-type="ref"} which was higher than the positive cut‐off values set in this study, and may influence the results. It is also important to note that for previous studies[26](#rth212177-bib-0026){ref-type="ref"}, [28](#rth212177-bib-0028){ref-type="ref"}, [29](#rth212177-bib-0029){ref-type="ref"} the cut‐off was determined in healthy US donors. In addition, the cut‐off threshold for determining seroprevalence may change with geographical location and/or the utilization of patient‐specific samples during validation of an assay. It is imperative therefore to standardize measurement of seroprevalence of AAV in hemophilia patients, not only as a single measurement but in a longitudional study as this may impact the eligibility and outcome of gene therapy.

We report a significant increase in seroprevalence of AAV8 in patients exposed to plasma products. There was also a significant increase in seroprevalence of both AAV5 and AAV8 in patients who were exposed to hepatitis C. Further investigation is required to establish the cause of increased seroprevalence due to plasma exposure and hepatitis C. However, transfusion transmitted infection cannot be discounted.

Seroprevalence was higher with increasing age in this study, which has been observed in previously. Evidence from healthy individuals in Japan showed that AAV infection occurred in childhood and seropositivity subsequently decreased, however there was a second increase of seropositivity after 30 years of age.[46](#rth212177-bib-0046){ref-type="ref"} Similarly, another Japanese study of healthy as well as hemophilia patients observed an increase in seropositivity with age.[47](#rth212177-bib-0047){ref-type="ref"}

4.1. Limitations {#rth212177-sec-0015}
----------------

As discussed previously, various factors influence the sensitivity of assays for measuring TAb and TI to AAV and these need to be considered while interpreting results. The number of positive patients differed depending on the type of assay and therefore both should be considered at this stage to screen potential patients for gene therapy. With currently available tests there is a variation in positive cut‐off values, therefore there needs to be a focus on standardising these assays. Measurement of AAV antibodies was only done at a single time point and evaluation of varying titer levels over time should be considered for future studies. Divergent methodology of the assays employed to measure AAV5 and AAV8 must be taken into consideration when interpreting results.

5. CONCLUSION {#rth212177-sec-0016}
=============

Despite progression in the current treatment of hemophilia A from plasma derived to recombinant products, natural exposure to AAV occurs at an early age, as shown in seroprevalence studies in both healthy and paediatric hemophilia populations.[20](#rth212177-bib-0020){ref-type="ref"}, [26](#rth212177-bib-0026){ref-type="ref"}, [43](#rth212177-bib-0043){ref-type="ref"} Therefore, screening may need to be considered for those most likely to respond to gene therapy with AAV vectors. It is currently unknown whether some level of seropositivity to AAV may be tolerated and clinical studies will need to evaluate the effect of preexisting immunity on the safety and efficacy of AAV mediated gene therapy. Further investigation is required to explore the link between increased seroprevalence in patients exposed to plasma products and Hepatitis C.
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